PEMRYDI RTU is the first and only ready-to-use presentation of pemetrexed for in...
The company hopes to work with stakeholders to improve access to biosimilars acr...
Eloxx reanalysed data from a Phase II trial that previously missed its efficacy ...
Cullgen received a $35m upfront payment and is eligible for several milestone-ba...
Lilly will work on the development, manufacture and commercialisation activities...
“It’s a setback in patient safety and surveillance,” one expert said, "and will ...
Endometriosis is in dire need of treatments, and a new study implicating a type ...
A top UnitedHealth executive said there's been “a meaningfully higher number” of...
This was supposed to be the new Biogen. Instead, the company's board saddled CEO...
This week on the First Opinion Podcast, Torie Bosch spoke with Gabriel Bosslet a...
No one should have to go through months of ongoing health issues and mental stre...
For three years, nine months, and one week, MIT professor Ram Sasisekharan lived...
The split threatens to splinter a national advocacy organization that has bolste...
This was supposed to be the new Biogen. Then came another boardroom controversy.
“We should break these PBMs up,” House Oversight Committee Chair James Comer (R-...
GOP lawmakers took predictable shots at CDC Director Rochelle Walensky during on...
